Last updated on November 2017

Alpha 1 Antitrypsin Deficiency


Brief description of study

Alpha 1 Antitrypsin Deficiency

Detailed Study Description

A stage 1, prospective, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of Alpha 1-proteinase Inhibitor (A1P1) augmentation therapy in subjects with A1P1 Deficiency and chronic obstructive pulmonary disease (COPD).

This study is an approximately 2 year study that will evaluate the safety and effectiveness of the FDA approved drugs Aralast NP and Glassia in COPD patients with Alpha 1 Antitrypsin Deficiency compared to placebo.

Clinical Study Identifier: TX9661

Contact Investigators or Research Sites near you

Start Over

Customer Service

Phoenix Medical Research
Peoria, AZ USA

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.